Protagenic - PTIX Company Value to Revenue

Protagenic Therapeutics (PTIX) develops synthetic peptides to combat depression, leveraging long-term patient demand. The company's price-to-sales ratio reflects the market reaction, where the value 0.00 expresses the current state of the metric. Future revenues are based on anxiety medications, although success depends on clearing clinical phases and maintaining strict control over R&D expenses.
Protagenic - analytical breakdowns and key metrics (PTIX)

This indicator determines the market value of the entire business minus net debt relative to sales volume, allowing for an assessment of the premium investors are paying per unit of revenue. When analyzing the enterprise value-to-revenue ratio, it should be noted that for Protagenic Therapeutics (PTIX), in the absence of commercial products and operating income, this metric reflects only the market's speculative expectations for future clinical success.